Ranbaxy Laboratories has issued 5,000 secured 9.20% Redeemable Non-Convertible Debentures (NCD) of face value of Rs 10,00,000 each, for cash at par, aggregating Rs 500 crore, on a private placement basis, for general corporate purposes. These debentures have been rated AA+ by CARE and are proposed to be listed on stock National Exchange of India (NSE).
In another development, the company had recalled Atorvastatin from the USA market which will cause temporary disruption to the market of this product.
Ranbaxy Laboratories is India's largest pharmaceutical company. The company has global presence in 49 countries and is ranked amongst top ten global generics companies. Ranbaxy has world-class manufacturing facilities in 11 countries namely Brazil, China, Ireland, India, Japan, Malaysia, Nigeria, Romania, South Africa, USA and Vietnam.
